Tuberculosis and Respiratory Diseases

  • 제81권3호
  • /
  • Pages.258-259
  • /
  • 2018
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

What is Currently the Best for Adenocarcinoma without Driver Mutation?

  • Park, Cheol-Kyu (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Oh, In-Jae (Department of Internal Medicine, Chonnam National University Medical School) ;
  • Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Medical School)
  • 투고 : 2018.03.22
  • 심사 : 2018.05.09
  • 발행 : 2018.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016;11:946-63. https://doi.org/10.1016/j.jtho.2016.05.008
  2. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017;15:504-35. https://doi.org/10.6004/jnccn.2017.0050
  3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. https://doi.org/10.1200/JCO.2007.15.0375
  4. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-902. https://doi.org/10.1200/JCO.2012.47.1102
  5. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-55. https://doi.org/10.1016/S1470-2045(12)70063-3
  6. Tomasini P, Barlesi F, Mascaux C, Greillier L. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther Adv Med Oncol 2016;8:198-208. https://doi.org/10.1177/1758834016644155
  7. Paik SS, Hwang IK, Park MJ, Lee SH. Pemetrexed continuation maintenance versus conventional platinum-based doublet chemotherapy in EGFR-negative lung adenocarcinoma: retrospective analysis. Tuberc Respir Dis 2018;81:148-55. https://doi.org/10.4046/trd.2017.0090
  8. Park S, Kim HJ, Choi CM, Lee DH, Kim SW, Lee JS, et al. Predictive factors for a long-term response duration in nonsquamous cell lung cancer patients treated with pemetrexed. BMC Cancer 2016;16:417. https://doi.org/10.1186/s12885-016-2457-0
  9. Xu CW, Wang G, Wang WL, Gao WB, Han CJ, Gao JS, et al. Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues. Exp Ther Med 2015;9:2151-4. https://doi.org/10.3892/etm.2015.2372
  10. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 2013;24:59-66. https://doi.org/10.1093/annonc/mds242
  11. Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, et al. Ana- plastic lymphoma kinase translocation: a predictive biomark- er of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474-80. https://doi.org/10.1097/JTO.0b013e3182208fc2